11 months ago
Kymriah Drug
Kymriah Drug Kymriah (Tisagenlecleucel) is a type of cancer treatment known as CAR T-cell therapy. It involves modifying a patient’s own T cells to target and kill cancer cells. Here’s ...
11 months ago
11 months ago
2024EHA | Professor Huang He: Targeting CD7 Universal CAR-T Therapy Shows Significant Efficacy and Good Safety in Treating R/R CD7+ T-ALL/LBL Patients
**2024EHA | Professor Huang He: Targeting CD7 Universal CAR-T Therapy Shows Significant Efficacy and Good Safety in Treating R/R CD7+ T-ALL/LBL Patients** The 29th Annual Meeting of the European H...
11 months ago
May 1, 2018 Kymriah DLBCL Approval in the U.S. FDA
May 1, 2018 Kymriah DLBCL Approval in the U.S. FDA On May 1, 2018, the FDA approved Kymriah for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL). Kymriah is ...
11 months ago
Kymriah Cell Therapy of CAR-T
Kymriah Cell Therapy of CAR-T Kymriah, also known by its generic name tisagenlecleucel, is a groundbreaking cell therapy used to treat certain types of blood cancers. Developed by Novartis, Kymriah...
11 months ago
Kymriah CD19-Targeted CAR-T Therapy
Kymriah CD19-Targeted CAR-T Therapy Kymriah (tisagenlecleucel) is a groundbreaking CAR-T (Chimeric Antigen Receptor T-cell) therapy developed for the treatment of certain types of blood cancers. He...
11 months ago
China’s Breakthrough in CAR-T Therapy for CNS Lymphoma
### China’s Breakthrough in CAR-T Therapy for CNS Lymphoma Lymphoma In a pioneering effort to improve outcomes for patients with refractory/relapsed central nervous system lymphoma (CNSL), a multi-...
11 months ago
China’s Urological Technology Leads the Way! Over 100 International Doctors from More than 40 Countries Come to Learn
China’s Urological Technology Leads the Way! Over 100 International Doctors from More than 40 Countries Come to Learn China’s Urological ## Innovative Breakthroughs in Urology ChinaR...
11 months ago
Kymriah CAR-T Cell Therapy: A Comprehensive Overview
Kymriah CAR-T Cell Therapy: A Comprehensive Overview Introduction Kymriah (tisagenlecleucel) represents a groundbreaking advancement in the field of immunotherapy. It is a chimeric antigen receptor...
12 months ago
Kymriah Approved Indications
Kymriah Approved Indications Kymriah (tisagenlecleucel) represents a groundbreaking advancement in the field of cancer immunotherapy. As a chimeric antigen receptor T-cell (CAR-T) therapy, Kymriah ...
12 months ago
Kymriah Approval FDA
Kymriah Approval FDA On April 22, 2020, Novartis announced that the U.S. Food and Drug Administration (FDA) granted Kymriah® (tisagenlecleucel) Regenerative Medicine Advanced Therapy (RMAT) designa...
12 months ago
Kymriah Approval DLBCL
Kymriah Approval DLBCL As of May 1, 2018, the FDA has approved Novartis’ CD19-targeted CAR-T therapy tisagenlecleucel (Kymriah) for the treatment of adult patients with relapsed or refractory...
12 months ago
Kymriah Approval Date
Kymriah Approval Date Introduction to Kymriah Kymriah (tisagenlecleucel) is a groundbreaking chimeric antigen receptor T-cell (CAR-T) therapy developed by Novartis. It represents a novel approach t...